Gynica, a company that focuses on clinically proven cannabis-based solutions in the field of women's health, developing optimal therapeutic results based on innovative technology and understanding of the pharmacological effects of different cannabinoids and compounds, targeted to specific female-related diseases, is collaborating with Lumir Lab, a research and development lab focused on cannabinoids, to find a cannabis-based treatment for endometriosis.
Who Is Gynica?
The Gynica team is led by the President of the European Association of Perinatal Medicine, Professor Moshe Hod, who is also a Tel Aviv University medical school professor of obstetrics and gynecology.
Commenting on the partnership, Yotam Hod, CEO and co-founder of Gynica told Benzinga that both his company and Lumir Lab are committed to discovering cannabis-based solutions to treat endometriosis and “finally put an end to the pain experienced by more than 176 million women worldwide.
“Specializing in R&D, quality control, and the development of custom formulations and delivery methods, we continue to explore and discover pioneering advancements in medical cannabis. We are dedicated to scientific research that leads to an improved quality of life, as we continue discovering, developing, and providing the leading innovations and solutions of the future.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.